N³-benzoyl-5-iodouracil | 161263-60-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N³-benzoyl-5-iodouracil
• 英文别名: 3-benzoyl-5-iodo-1H-pyrimidine-2,4-dione
• CAS: 161263-60-1
• 化学式: C₁₁H₇IN₂O₃
• 分子量: 342.093
• InChiKey: IFJZHMIMIMJXJU-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205 °C
• 密度：
  1.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N³-benzoyl-5-iodouracil 在 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 0.5h， 生成 1-[4-acetoxy-3-(acetoxymethyl)butyl]-3-benzoyl-5-[(3,5-difluorophenyl)ethynyl]pyrimidine-2,4-dione
  参考文献：
  名称：

  Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides

  摘要：

  A series of novel N-acyclic uracil analogs with linear, branched, aromatic, and cyclopropyl-alkynyl as well as heteroaryl moieties at C-5 were prepared using palladium catalyzed Sonogashira and Stifle cross-coupling and evaluated against malignant tumor cell lines. C-5-Furan-2-yl uracil derivative 6 was shown to be more potent against MCF-7 than the reference drug 5-fluorouracil (5-FU), while C-5-alkynyl uracil derivatives 9c and 9e exhibited antibreast cancer activities comparable to 5-FU. Selected compounds induced cell death, partially due to apoptosis, of MCF-7 breast cancer cells. Abrogation of acid ceramidase (ASAH1) expression of 9c and 9e indicated that these compounds could perturb ASAH1-mediated sphingolipid signaling. The selective activity of 9c and 9e against breast cancer cells via the ASAH1-mediated signaling, potential future therapeutic use. as a molecular target, might have a great advantage for potential future therapeutic use.

  DOI：

  10.1021/acsmedchemlett.5b00298
• 作为产物：
  描述：

  3-苯甲酰基尿嘧啶 在 ammonium cerium (IV) nitrate 、 碘 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以65%的产率得到N³-benzoyl-5-iodouracil
  参考文献：
  名称：

  Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides

  摘要：

  A series of novel N-acyclic uracil analogs with linear, branched, aromatic, and cyclopropyl-alkynyl as well as heteroaryl moieties at C-5 were prepared using palladium catalyzed Sonogashira and Stifle cross-coupling and evaluated against malignant tumor cell lines. C-5-Furan-2-yl uracil derivative 6 was shown to be more potent against MCF-7 than the reference drug 5-fluorouracil (5-FU), while C-5-alkynyl uracil derivatives 9c and 9e exhibited antibreast cancer activities comparable to 5-FU. Selected compounds induced cell death, partially due to apoptosis, of MCF-7 breast cancer cells. Abrogation of acid ceramidase (ASAH1) expression of 9c and 9e indicated that these compounds could perturb ASAH1-mediated sphingolipid signaling. The selective activity of 9c and 9e against breast cancer cells via the ASAH1-mediated signaling, potential future therapeutic use. as a molecular target, might have a great advantage for potential future therapeutic use.

  DOI：

  10.1021/acsmedchemlett.5b00298

文献信息

• [EN] AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] DÉRIVÉS D'AZABICYCLO[3.1.0]HEXYLE EN TANT QUE MODULATEURS DE RÉCEPTEURS DOPAMINERGIQUES D3
  申请人：GLAXO GROUP LTD

  公开号：WO2009043883A1

  公开（公告）日：2009-04-09

  The present invention relates to novel compounds of formula (I) or a salt thereof: wherein R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5, and n is 1 or 2; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

  本发明涉及式(I)的新化合物或其盐：其中R1是一个5-成员杂芳基团，可选地与一个6-成员杂环或碳环融合；这样的5或11-成员体系，可以选择地由卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基、卤代C1-4烷氧基和SF5中的1、2、3或4个取代基取代，并且n为1或2；其制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们在治疗中的用途，作为多巴胺D3受体调节剂，例如用于治疗药物依赖、作为抗精神病药物、用于治疗强迫症谱系障碍或早泄。
• Acyclic Nucleoside Analogues as Novel Inhibitors of Human Mitochondrial Thymidine Kinase
  作者：Ana-Isabel Hernández、Jan Balzarini、Anna Karlsson、María-José Camarasa、María-Jesús Pérez-Pérez

  DOI：10.1021/jm011128+

  日期：2002.9.1

  A series of acyclic nucleoside analogues of 5'-O-tritylthymidine have been synthesized and evaluated as potential human mitochondrial thymidine kinase (TK-2) inhibitors. In this series, the sugar moiety of the parent 5'-O-tritylthymidine has been replaced by aliphatic chains including (E)- and (Z)-butenol, butynol, or butanol. Among them the (Z)-butenyl derivative (10) showed an IC(50) against TK-2

  已合成了一系列5'-O-三苯甲基胸苷的无环核苷类似物，并被评估为潜在的人线粒体胸苷激酶（TK-2）抑制剂。在该系列中，母体5'-O-三苯甲基胸苷的糖部分已被包括（E）-和（Z）-丁烯醇，丁炔醇或丁醇的脂族链取代。其中（Z）-丁烯基衍生物（10）对TK-2的IC（50）为1.5 microM，比母体5'-O-三苯甲基胸苷的效力高1个数量级。通过用其他嘧啶碱基（例如5-碘尿嘧啶，5-乙基尿嘧啶，5-甲基胞嘧啶，3-N-甲基胸腺嘧啶或5,6-二氢胸腺嘧啶）取代胸腺嘧啶碱基以及嘌呤碱基，进一步修饰了该先导化合物鸟嘌呤。三苯甲基也被不同的脂族和芳族酰基部分所取代，包括叔丁基乙酰基，己酰基，癸酰基和二苯乙酰基部分。对化合物针对TK-2和系统发育接近的HSV-1 TK的评估表明，碱基部分在它们与这些嘧啶核苷激酶的相互作用中起着至关重要的作用。同样，为了有效抑制TK-2，需要存在亲脂性取代基，优选为芳族部
• Synthesis of Chiral Acyclic Nucleosides by Sharpless Asymmetric Dihydroxylation: Access to Cidofovir and Buciclovir
  作者：Tao Qin、Jian-Ping Li、Ming-Sheng Xie、Gui-Rong Qu、Hai-Ming Guo

  DOI：10.1021/acs.joc.8b02442

  日期：2018.12.21

  nucleosides via Sharpless asymmetric dihydroxylation of N-allylpyrimidines or N-alkenylpurines is reported. A range of chiral acyclic nucleosides with two adjacent hydroxyl groups present on the side chains could be produced in good yields (up to 97% yield) and excellent enantioselectivities (90–99% ee). The synthetic utility of the reaction was demonstrated by the catalytic asymmetric synthesis of (S)-Cidofovir

  报道了一种通过N-烯丙基嘧啶或N-烯基嘌呤的Sharpless不对称二羟基化来构建手性无环核苷的有效方法。可以以高收率（最高97％的收率）和出色的对映选择性（90-99％ee）生产一系列在侧链上带有两个相邻羟基的手性无环核苷。通过（S）-西多福韦和（R）-比昔洛韦的催化不对称合成证明了该反应的合成效用。
• Enantioselective synthesis of chiral carbocyclic pyrimidine nucleosides via asymmetric cyclopropanation
  作者：Hai-Xia Wang、Wen-Peng Li、Chao Xia、Ming-Sheng Xie、Gui-Rong Qu、Hai-Ming Guo

  DOI：10.1016/j.tetlet.2019.151183

  日期：2019.10

  pyrimidine carbocyclic nucleoside analogues bearing a quaternary center was developed via asymmetric Michael-initiated cyclopropanation. The axis chirality was observed in cyclopropyl pyrimidine carbocyclic nucleoside analogues for the first time, which was caused by the rotationally restricted NC bond in N-COPh moiety. Using (DHQD)2AQN as the organocatalyst, diverse cyclopropyl pyrimidine carbocyclic nucleoside

  通过不对称迈克尔引发的环丙烷化，开发了一种构建带有季中心的手性环丙基嘧啶碳环核苷类似物的有效方法。首次在环丙基嘧啶碳环核苷类似物中观察到轴手性，这是由N -COPh部分中受旋转限制的N C键引起的。使用（DHQD）2 AQN作为有机催化剂，可以产生76-93％的收率和73-96％ee的多种环丙基嘧啶碳环核苷类似物。
• Regio- and Enantioselective Synthesis of Chiral Pyrimidine Acyclic Nucleosides via Rhodium-Catalyzed Asymmetric Allylation of Pyrimidines
  作者：Lei Liang、Ming-Sheng Xie、Tao Qin、Man Zhu、Gui-Rong Qu、Hai-Ming Guo

  DOI：10.1021/acs.orglett.7b02482

  日期：2017.10.6

  A direct route to branched N-allylpyrimidine analogues is herein reported via the highly regio- and enantioselective asymmetric allylation of pyrimidines with racemic allylic carbonates. With [Rh(COD)Cl]2/chiral diphosphine as the catalyst, a range of chiral pyrimidine acyclic nucleosides could be obtained under neutral conditions in good yields (up to 95% yield) with high levels of regio- and enantioselectivities

  本文报道了通过嘧啶与外消旋烯丙基碳酸酯的高度区域-和对映选择性不对称烯丙基化而形成支化N-烯丙基嘧啶类似物的直接途径。以[Rh（COD）Cl] 2 /手性二膦为催化剂，可以在中性条件下以良好的收率（高达95％的收率）获得一系列手性嘧啶无环核苷，并具有较高的区域和对映选择性（15： 1至> 40：1提单数据，最高ee达99％）。此外，已经通过不对称二羟基化成功地合成了带有两个相邻手性中心的手性嘧啶无环核苷。